

# Brenda Moura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/554612/publications.pdf>

Version: 2024-02-01

30  
papers

1,485  
citations

430754

18  
h-index

454834

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1780  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	2.9	29
2	Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	2.9	22
3	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	2.9	181
4	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. European Heart Journal, 2021, 42, 657-670.	1.0	25
5	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. European Journal of Heart Failure, 2021, 23, 906-914.	2.9	130
6	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. Cardiologia Croatica, 2021, 16, 140-156.	0.0	0
7	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	2.9	23
8	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	2.9	32
9	From left ventricular ejection fraction to cardiac hemodynamics: role of echocardiography in evaluating patients with heart failure. Heart Failure Reviews, 2020, 25, 217-230.	1.7	27
10	Heart Failure Association of the European Society of Cardiology update on sodium-glucose cotransporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	2.9	66
11	Sodium-glucose cotransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100
12	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association of the European Society of Cardiology (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 1504-1524.	2.9	234
13	The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645.	2.9	23
14	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-ORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36
15	Genetic variants identified by target next-generation sequencing in heart transplant patients with dilated cardiomyopathy. Revista Portuguesa De Cardiologia, 2019, 38, 441-447.	0.2	10
16	Genetic Variants Are Not Rare in ICD Candidates with Dilated Cardiomyopathy: Time for Next-Generation Sequencing?. Cardiology Research and Practice, 2019, 2019, 1-9.	0.5	3
17	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	2.9	224
18	Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction. International Journal of Cardiovascular Imaging, 2017, 33, 605-613.	0.7	16

#	ARTICLE	IF	CITATIONS
19	The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 709-716.	0.2	11
20	The role of biomarkers in dilated cardiomyopathy: Assessment of clinical severity and reverse remodeling. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 709-716.	0.2	5
21	Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 253-260.	0.2	11
22	Prevalence, predictors and prognosis of ventricular reverse remodeling in idiopathic dilated cardiomyopathy. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 253-260.	0.2	20
23	Iron Deficiency Status Irrespective of Anemia: A Predictor of Unfavorable Outcome in Chronic Heart Failure Patients. <i>Cardiology</i> , 2014, 128, 320-326.	0.6	40
24	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
25	Portuguese study of familial dilated cardiomyopathy: the FATIMA study. <i>Revista Portuguesa De Cardiologia</i> , 2008, 27, 1029-42.	0.2	12
26	Pericardial Involvement in Human Immunodeficiency Virus Infection. <i>Chest</i> , 1999, 115, 418-422.	0.4	51
27	Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. <i>International Journal of Cardiology</i> , 1998, 63, 37-45.	0.8	44
28	Predictors of myocardial dysfunction in human immunodeficiency virus-infected patients. <i>Journal of Cardiac Failure</i> , 1998, 4, 19-26.	0.7	6
29	Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients. <i>International Journal of Cardiology</i> , 1997, 59, 285-289.	0.8	16
30	Zidovudine Therapy and Left Ventricular Function and Mass in Human Immunodeficiency Virus-Infected Patients. <i>Cardiology</i> , 1997, 88, 26-28.	0.6	10